Quintiles News

Please select a press release from the list below, or filter and sort to find a specific press release.

Latest Press Release

Quintiles Introduces Infosario One Mobile App

RESEARCH TRIANGLE PARK, N.C. – June 16, 2015 – Quintiles, the world’s largest biopharmaceutical services company, is extending its award-winning Quintiles Infosario ® technology platform with mobile access to critical clinical trial information. Using the mobile app, key stakeholders in the drug development process can conveniently access site start-up, recruitment and compliance information as well as status updates on data queries and project milestones. “With so... Learn More
Published Date: All 2015 2014 2013 2012 2011 2010
Press Release Jun 16, 2015
RESEARCH TRIANGLE PARK, N.C. – June 16, 2015 – Quintiles, the world’s largest biopharmaceutical services company, is extending its award-winning Quintiles Infosario® technology platform with mobile access to critical clinical trial information. Using the mobile app, key stakeholders in the drug development process can conveniently access site start-up, recruitment and compliance information as well as status updates on data queries and project milestones. “With so much at stake in the successful delivery of development programs, faster decision making is fundamental,” said Margaret Keegan, senior vice president of Data Sciences & Strategy at Quintiles. “Infosario One provides instant and intuitive access to insights at your fingertips, wherever and whenever you need them.” The Infosario...
Read More
Press Release Jun 15, 2015
RESEARCH TRIANGLE PARK, N.C. – June 15, 2015 – Quintiles, the world’s largest biopharmaceutical services company, today announced the addition of advanced statistical monitoring and predictive analytics capabilities to its risk-based monitoring (RBM) solution. Predictive and Advanced Analytics combine Quintiles’ experience as the RBM leader with its deep therapeutic and strong statistical sciences heritage to enable study teams to identify the right signals and predict clinical trial site performance and potential patient safety issues. Predictive and Advanced Analytics are the first such model-based capabilities fully integrated into an RBM solution on the market today. Underpinned by the award-winning Quintiles Infosario® technology platform and Quintiles’ deep data resources, these new...
Read More
Press Release Jun 02, 2015
RESEARCH TRIANGLE PARK, N.C. – June 2, 2015 – Quintiles CEO Tom Pike will present at the Jefferies 2015 Global Healthcare Conference on Wednesday, June 3 in New York City at the Grand Hyatt New York. Pike’s presentation was rescheduled from Tuesday after multiple, weather-related flight cancellations kept him for reaching the conference as planned. The Quintiles presentation will now begin at 10:00 a.m. EDT on Wednesday. Investors may access a live audio webcast of the presentation on the Quintiles’ investor relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later in the day Wednesday, June 3rd. About Quintiles Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and...
Read More
Press Release May 29, 2015
SHANGHAI – 29 May 2015 – More than 30 leaders from China’s government and healthcare communities joined Quintiles executives here today in officially opening the Quintiles Greater China Regional Headquarters, further expanding its ability to help Chinese companies expand globally and multinational companies succeed in the world’s second largest biopharmaceutical market. The event comes 17 years after Quintiles first opened an office in Shanghai. “Today we celebrate not only Quintiles’ growth, but also Greater China’s emergence as a global player in biopharma R&D,” said Quintiles founder and Executive Chairman Dennis Gillings, CBE, Ph.D., at the opening ceremony at Shanghai’s Feng Lin Science Park. “Two decades ago we opened in Shanghai with 20 employees across Greater China – now we...
Read More
Press Release May 25, 2015
SINGAPORE – 25 May 2015 – To help Asia-Pacific emerging biopharmaceutical companies achieve their growth aspirations, Quintiles today launched a new solution set tailored to meet the needs of emerging companies in the world’s most diverse and dynamic healthcare market. “Asia-Pacific is poised to become the world’s next biopharma powerhouse, not least because of its growing number of emerging companies with promising pipelines,” said Senior Vice President Ross Horsburgh, M.D., Quintiles Head of Clinical Development, Asia-Pacific.  “These companies face formidable challenges as they look to expand into markets or therapeutic areas in which they may have limited or no experience.   “From start-ups to larger emerging players, our Asia-Pac solution is designed to improve their probability...
Read More
Press Release May 20, 2015
RESEARCH TRIANGLE PARK, N.C. – May 20, 2015 – Quintiles CEO Tom Pike will present at the Jefferies 2015 Global Healthcare Conference on Tuesday, June 2, 2015 in New York City at the Grand Hyatt New York. The Quintiles presentation will begin at 11:30 a.m. (EDT). Investors may access a live audio webcast of the presentation on the Quintiles’ investor relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 33,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2014’s top-75...
Read More
Press Release May 19, 2015
RESEARCH TRIANGLE PARK, NC – May 19 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the closing of an underwritten, secondary public offering of 11,855,050 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation, Temasek Life Sciences Private Limited and Dennis Gillings, CBE, and his affiliates (the “Selling Shareholders”) at a price to the public of $65.00 per share. Of the total shares sold in the offering, Quintiles repurchased 3,855,050 shares from the underwriters at a price of $64.85 per share, which is the same as the price per share paid to the Selling Shareholders by the underwriters. Quintiles did...
Read More
Press Release May 14, 2015
Research Triangle Park, NC, May 14, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the pricing of an underwritten, secondary public offering of 11,855,050 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation, Temasek Life Sciences Private Limited and Dennis Gillings, CBE, and his affiliates (the “Selling Shareholders”) at a price to the public of $65.00 per share. Quintiles intends to repurchase from the underwriters a number of shares having an aggregate value of approximately $250 million. Quintiles is not offering any stock in this transaction and will not receive any proceeds from the sale of the...
Read More
Press Release May 13, 2015
Research Triangle Park, NC, May 13, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the launch of an underwritten, secondary public offering of 11,855,050 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation, Temasek Life Sciences Private Limited and Dennis Gillings, CBE, and his affiliates (the “Selling Shareholders”), of which Quintiles intends to repurchase from the underwriters a number of shares having an aggregate value of approximately $250 million. Quintiles is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Shareholders in this...
Read More
Press Release May 12, 2015
RESEARCH TRIANGLE PARK, NC – May 12, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) (the “Company” or “Quintiles”) today announced the completion of its previously announced refinancing.  In the refinancing, the Company’s wholly-owned subsidiary, Quintiles Transnational Corp. (“Quintiles Transnational”), entered into new senior secured credit facilities totaling $1.95 billion, consisting of a $500 million revolving credit facility and $1.45 billion of term loans. In addition, Quintiles Transnational completed the offering of its $800 million principal amount of 4.875% senior unsecured notes due 2023 (the “Senior Notes”) in a private placement that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”).  Net proceeds from the...
Read More
Press Release May 06, 2015
RESEARCH TRIANGLE PARK, NC – May 6, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) (the “Company” or “Quintiles”) announced today that Quintiles Transnational Corp. (“Quintiles Transnational”), its wholly owned subsidiary, has priced $800 million principal amount of 4.875% senior unsecured notes due 2023 (the “Senior Notes”) offered in a private placement that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Company intends to use the net proceeds of the offering, together with proceeds from its previously announced proposed senior secured credit facility, which is expected to increase to a total of $1.95 billion, including $1.45 billion of term loans, to refinance its existing credit facility, as well as for...
Read More
Press Release May 04, 2015
RESEARCH TRIANGLE PARK, NC – May 4, 2015 – Quintiles today announced the expansion of its bioanalytical laboratory services with the establishment of a GLP-compliant bioanalytical liquid chromatography-mass spectrometry (LC-MS) laboratory. The laboratory, which is located in Oss, the Netherlands, will have extensive bioanalytical testing capabilities and will provide a European facility for Quintiles customers to conduct pharmacokinetics studies.  The Oss laboratory facility combines a cohort of employees with extensive industry experience, automated processes, and a state-of-the-art facility equipped to increase high-quality throughput. The new laboratory is led by Dr. Benno Ingelse, an industry expert with more than 15 years of (bio)analytical experience.  In addition, the Oss...
Read More
Press Release May 04, 2015
Research Triangle Park, NC - Quintiles CFO Kevin Gordon will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015 in Las Vegas at the Encore Wynn. The Quintiles presentation will begin at 12:00 p.m. PDT. Investors may access a live audio webcast of the presentation on the Quintiles’ Investor Relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 33,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-75 best-selling drugs on the market....
Read More
Press Release May 01, 2015
RESEARCH TRIANGLE PARK, N.C. – May 1, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) (the “Company” or “Quintiles”) announced today a proposed offering by its wholly owned subsidiary, Quintiles Transnational Corp. (“Quintiles Transnational”), of $800 million principal amount of senior unsecured notes due 2023 (the “Senior Notes”), subject to market and other conditions. The Senior Notes will be offered in a private placement that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Company intends to use the net proceeds of the offering, together with proceeds from its previously announced proposed new senior secured credit facility, to refinance its existing credit facilities, as well as for general corporate...
Read More
Press Release Apr 30, 2015
RESEARCH TRIANGLE PARK, N.C. – April 30, 2015 – Quintiles, the world’s largest biopharmaceutical services company, has been named to the InformationWeek Elite 100, a ranking of the top business technology innovators in the U.S. In compiling the InformationWeek Elite 100, the publication tracks the technology-based investments, strategies and results of some of the best-known organizations in the country.  Unique among corporate rankings, the Elite 100 spotlights the power of business technology innovation.  Quintiles was previously named to the InformationWeek 500 for five consecutive years. Accelerating the Clinical Trial Process:  Quintiles Infosario® Site Targeting Quintiles was named to the 2015 InformationWeek Elite 100 for its innovative Quintiles Infosario Site Targeting...
Read More
Press Release Apr 29, 2015
RESEARCH TRIANGLE PARK, N.C., April 29, 2015 – Quintiles Transnational Holdings Inc. (the “Company” or “Quintiles”) (NYSE: Q) announced today that it is proposing, subject to market and other conditions, to enter into $1.75 billion of new senior secured credit facilities consisting of a $500 million revolving credit facility and $1.25 billion of term loans, and to issue $800 million aggregate principal amount of unsecured debt.  The Company intends to use the net proceeds of the offering of the unsecured debt, together with the new term loans, to refinance its existing credit facilities, as well as for general corporate purposes, including corporate transactions and equity repurchases.  The refinancing transactions would be entered by Quintiles Transnational Corp., the Company’s...
Read More
Press Release Apr 29, 2015
Research Triangle Park, NC, April 29, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) today reported its financial results for the quarter ended March 31, 2015. $1.35 billion of net new business representing a 1.31 book-to-bill ratio 8.4% constant currency service revenue growth compared to the first quarter of 2014 $0.72 diluted adjusted earnings per share representing 5.9% growth compared to the first quarter of 2014 and first quarter GAAP reported diluted earnings per share of $0.68 Updating full year 2015 service revenue constant currency growth guidance to 7.0% - 8.0% compared to full year 2014 and reaffirming diluted adjusted EPS guidance of $3.02 - $3.13 per share, representing diluted adjusted EPS growth of 12% to 16% compared...
Read More
Press Release Apr 16, 2015
RESEARCH TRIANGLE PARK, N.C. – April 16, 2015 – Quintiles today announced a strategic alliance with Hospital Italiano of Buenos Aires as part of the company’s Prime Site program. Hospital Italiano is Quintiles’ first Prime Site in Latin America, complementing the company’s robust network of investigative sites across the globe. A Prime Site is a large clinical institution selected by Quintiles to work together and enhance the institution’s infrastructure for conducting clinical trials in order to accelerate the development of new and more effective medicines. Quintiles and a Prime Site work together to create a more efficient clinical trial process by recruiting, enrolling and retaining more patients through the course of a clinical trial. The new agreement with Hospital Italiano is...
Read More
Press Release Apr 09, 2015
RESEARCH TRIANGLE PARK, N.C. – April 9, 2015 – For the third time in the last four years, Quintiles has been named Best Clinical Research Organization (CRO) at the Vaccine Industry Excellence (ViE) Awards. Presented at the World Vaccine Congress in Washington, D.C., the awards recognize the efforts and achievements of companies and individuals in the vaccine industry during the previous year. “We are honored to once again receive this prestigious award reflecting the insight of many from across the biopharmaceutical industry,” said Phil Breitfeld, vice president and head of the Therapeutic Centers of Excellence at Quintiles. “It is clear to us all that the healthcare industry has a tremendous opportunity to conquer the global burden of disease. We’re proud to be working alongside our...
Read More
Press Release Mar 31, 2015
Combines the complementary strengths and scale of leading biopharmaceutical services and diagnostic information services providers New entity creates superior value proposition through the depth and scale of its capabilities, services and expertise Business to help biopharmaceutical customers bring new drug therapies to market and support precision medicine Joint venture would have generated approximately $575 million in revenues in 2014 Quintiles will own 60% and Quest Diagnostics will own 40% of the joint venture Investor teleconference scheduled for March 31 at 8:30 a.m. ET RESEARCH TRIANGLE PARK, N.C. and MADISON, N.J. – March 31, 2015 – Quintiles and Quest Diagnostics today announced a definitive agreement to form a global clinical trials laboratory services...
Read More